Agenus Inc.

Healthcare · Biotechnology · United States

Last price 6.84 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 307.94M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte ...